Passage Bio to Host Virtual R&D Event on May 17

Rhea-AI Summary

Passage Bio (Nasdaq: PASG) will host its second virtual Research & Development event on May 17, 2021, focusing on frontotemporal dementia (FTD) with granulin mutations. This presentation will include robust pre-clinical data and insights into the clinical program for PBFT02, a gene therapy for FTD. Key speakers include Eliseo O. Salinas and Christian Hinderer, among others. The event will feature a Q&A session with prominent experts. The live webcast will be accessible on the company's website for 30 days after the event.

Focus to be on frontotemporal dementia with granulin mutations

PHILADELPHIA, May 10, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced it will host its second virtual Research & Development event on Monday, May 17, 2021, from 9:30 to 11:30 a.m., Eastern Time.

The event will focus on frontotemporal dementia (FTD) with granulin (GRN) mutations, providing a detailed presentation of the company’s robust pre-clinical data and clinical program. Presenters for the event are:

• Eliseo O. Salinas, M.D. MSc., chief R&D officer, Passage Bio
• Christian Hinderer, M.D., Ph.D., senior research director at the Gene Therapy Program (GTP), University of Pennsylvania
• Gary Romano, M.D., Ph.D., chief medical officer, Passage Bio
• The presenters will also be joined during a Q&A session by Bruce Goldsmith, Ph.D., president and chief executive officer, Passage Bio; and James M. Wilson, M.D., Ph.D., director, GTP, University of Pennsylvania, and chief scientific advisor at Passage Bio

To register for the live event, please use the following link: https://www.webcaster4.com/Webcast/Page/359/41012

A live webcast of the presentation will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com and will remain active for 30 days.

About Frontotemporal Dementia

FTD is one of the more common causes of early-onset (midlife) dementia, causing impairment in behavior, language and executive function, and occurs at similar frequency to Alzheimer’s disease in patients younger than 65 years. In approximately 5% to 10% of individuals with FTD, the disease occurs because of mutations in the GRN gene, causing a deficiency of progranulin (PGRN). PGRN is a complex and highly conserved protein. The mechanism by which PGRN deficiency results in FTD is uncertain, but increasing evidence points to PGRN’s role in lysosomal function. The rapid progression of FTD results in an average survival of eight years after onset of symptoms.

About PBFT02

Passage Bio is developing PBFT02, an adeno-associated virus-delivery gene therapy, for the treatment of patients with FTD with GRN mutations in a global clinical Phase 1 /2 study titled upliFT-D.

More information about upliFT-D can be found at ClinicalTrials.gov: NCT04747431.

About Passage Bio

At Passage Bio (Nasdaq: PASG), we are on a mission to provide life-transforming gene therapies for patients with rare, monogenic CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with the communities we serve. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. This provides our team with enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies into clinical testing. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995, including, but not limited to: our expectations about timing and execution of anticipated milestones, including our planned IND submissions, initiation of clinical trials and the availability of clinical data from such trials; our expectations about our collaborators’ and partners’ ability to execute key initiatives; our expectations about manufacturing plans and strategies; our expectations about cash runway; and the ability of our lead product candidates to treat the underlying causes of their respective target monogenic CNS disorders. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “potential,” “possible,” “will,” “would,” and other words and terms of similar meaning. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our ability to develop and obtain regulatory approval for our product candidates; the timing and results of preclinical studies and clinical trials; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events; the risk that positive results in a preclinical study or clinical trial may not be replicated in subsequent trials or success in early stage clinical trials may not be predictive of results in later stage clinical trials; failure to protect and enforce our intellectual property, and other proprietary rights; our dependence on collaborators and other third parties for the development and manufacture of product candidates and other aspects of our business, which are outside of our full control; risks associated with current and potential delays, work stoppages, or supply chain disruptions caused by the coronavirus pandemic; and the other risks and uncertainties that are described in the Risk Factors section in documents the company files from time to time with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. Passage Bio undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

For further information, please contact:

Passage Bio Investors:

Stuart Henderson
Passage Bio
267-866-0114
shenderson@passagebio.com

Passage Bio Media:

Gwen Fisher
Passage Bio
215-407-1548
gfisher@passagebio.com

FAQ

What is the purpose of Passage Bio's event on May 17, 2021?

The event focuses on frontotemporal dementia with granulin mutations, presenting pre-clinical data and clinical programs.

Who are the presenters at the Passage Bio event?

Presenters include Eliseo O. Salinas, Christian Hinderer, and Gary Romano, among others.

What is PBFT02 and its relevance?

PBFT02 is a gene therapy developed by Passage Bio for treating frontotemporal dementia with granulin mutations.

How can I access the webcast of the Passage Bio event?

The webcast will be available on Passage Bio's Investors & Media website section for 30 days.

What is frontotemporal dementia?

Frontotemporal dementia is a common cause of early-onset dementia, often linked to granulin mutations.